RP1 treats large injected & uninjected tumors

RP1 is our first Immulytic product to enter the clinic, and is based on a proprietary strain of herpes simplex virus engineered for tumor selectivity and enhanced systemic potency through the expression of a potent fusogenic glycoprotein. This increases tumor killing potency 5-100 fold, and results in highly immunogenic cell death.

Tumors were induced in a dual flank pre-clinical model. RP1 was then injected into one tumor only. Each line on the graph represents an individual tumor. Both injected & uninjected tumors are effectively treated.